Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $41.33 Consensus PT from Brokerages

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last […]

Related Keywords

United States ,China ,America ,Sarah Boyce ,Arthura Levin ,Quadrant Capital Group ,Daiwa Securities Group Inc ,Needham Company ,Nisa Investment Advisors ,Cantor Fitzgerald ,China Universal Asset Management Co ,Securities Exchange Commission ,Nasdaq ,Avidity Biosciences Inc ,Avidity Biosciences ,Get Free Report ,Biosciences Stock Down ,Director Arthur ,Exchange Commission ,Investment Advisors ,Capital Group ,Investment Management ,Universal Asset Management ,Daiwa Securities Group ,Securities Group ,Get Free ,Avidity Biosciences Daily ,